Precision Medicine (Rx) Pipeline: Ignyta’s Molecularly Targeted Therapies

At Ignyta, our Rx (therapeutic) efforts are focused on developing and commercializing molecularly targeted therapies that help eradicate cancer. We believe these powerful precision medicines represent the future of cancer treatment, giving healthcare providers new tools in the battle against molecularly defined malignancies.

Learn more below about Ignyta’s portfolio of precision therapeutics in development, and visit our clinical trials page to find out more about getting your patients enrolled in a trial of one of Ignyta’s groundbreaking targeted therapies.

 

Take a Look into Ignyta’s Development Pipeline

Our precision medicine (Rx) pipeline, working hand-in-hand with our molecular diagnostic (Dx) technologies, creates the combined Rx/Dx capability that sets Ignyta apart from others, resulting in potentially faster determination of patient eligibility for an Ignyta clinical trial.

Ignyta's pipeline of precision cancer medicines in development; targeting the genomic causes of some cancers.
Ignyta's pipeline of precision cancer medicines in development; targeting the genomic causes of some cancers.

By taking several different approaches to halt cancer progression, Ignyta is developing molecularly and immunologically targeted therapies that, sequentially or in combination, are intended to eradicate residual disease.

Entrectinib – Targeting NTRK and ROS1 Fusions

Currently undergoing STARTRK-2, a global, potentially registration enabling Phase 2 clinical trial, entrectinib is a potent, CNS-active, orally available, selective tyrosine kinase inhibitor of the TRKA, TRKB, TRKC and ROS1 proteins. This product candidate was designed to target cancers harboring activating molecular alterations to the corresponding subset of oncogenes. Learn more about gene fusions in cancer, data from the entrectinib ongoing Phase I and Phase II trials, and clinical responses. Click here to Learn more about Entrectinib (RXDX-101), and NTRK and ROS1 Fusions as well as data from the entrectinib ongoing Phase I and Phase II trials, and clinical responses.

RXDX-105 – Targeting RET and Other Kinase Targets

An orally available, VEGF-sparing, potent RET inhibitor. A Phase Ib basket study of RXDX-105 has completed enrollment.
Learn more about RET fusions.

Taladegib – Targeting Hh/SMO

A small molecule hedgehog/smoothened inhibitor. In normal cells, the hedgehog molecule acts as a ligand that can bind the smoothened transmembrane receptor and set off a signaling cascade that can influence early development and replication of adult stem cell populations. Stem cells that acquire molecular changes activating the hedgehog/smoothened pathway can transform into tumor precursors; this process has been implicated in some forms of brain cancer, skin cancer, and pancreatic cancer. Targeting these stem cells in combination with other therapeutics could potentially help eradicate residual disease.

RXDX-106 – Targeting TYRO3, AXL, MER

RXDX-106 is a novel small molecule immunomodulatory agent with potent anti-tumor activity, alone and in combination with checkpoint inhibitors, that appears to restore and enhance overall immune function by reversing immunosuppression of innate immune cells in the tumor microenvironment (TME) through TYRO3, AXL, and MER (TAM) receptor tyrosine kinase (RTK) inhibition that is in late preclinical development.
Learn more about Pan-TAM Inhibitors.

The Rx/Dx Advantage

Decoding the underlying causes of cancer is an evolving field, with much at stake from all sides. Learn more about Ignyta’s Rx/Dx Advantage and how we’re working with healthcare providers to change cancer treatment and care.

Ignyta Scientific Presentations

A database of Ignyta’s clinical, scientific, and technical data on precision therapeutic candidates and diagnostic tests. See Ignyta’s Scientific and Clinical Presentations.